[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Lactomason Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":76},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100634372","effect-of-lactiplantibacillus-plantarum-lm1001-on-muscle-strength-in-older-adults-100634372",false,"NCT07538830","Effect of Lactiplantibacillus Plantarum LM1001 on Muscle Strength in Older Adults","A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Effects of Lactiplantibacillus Plantarum LM1001 on Muscle Strength in Older Adults.","Inclusion Criteria:\n\n* Adults aged 50 to 84 years (male or female)\n* Body mass index (BMI) between 18.5 and 30.0 kg\u002Fm²\n* Reduced skeletal muscle mass (≤110% of standard value by BIA)\n* Decreased handgrip strength according to age- and sex-specific criteria\n* Short Physical Performance Battery (SPPB) score over 9\n* Able to perform normal physical activity and provide written informed consent\n\nExclusion Criteria:\n\n* Clinically significant acute or chronic diseases requiring treatment\n* Conditions affecting muscle function or physical performance (e.g., severe musculoskeletal, neurological, or cognitive disorders, including sarcopenia)\n* Significant gastrointestinal disorders or history of major gastrointestinal surgery\n* Severe psychiatric disorders or recent use of antipsychotic medications\n* Respiratory diseases affecting lung function\n* Excessive alcohol intake, substance abuse, or heavy smoking\n* Known hypersensitivity to the investigational product or its components\n* Recent use of medications or supplements affecting muscle function or gut microbiota (e.g., antibiotics, probiotics, steroids)\n* Regular high-intensity or resistance exercise\n* Clinically significant abnormal laboratory findings or uncontrolled medical conditions\n* Recent fractures within the past year\n* Participation in another clinical trial within 3 months prior to screening\n* Pregnant or breastfeeding women\n* Individuals unable to communicate or ambulate\n* Any other condition deemed unsuitable by the investigator",true,"ALL","50 Years","85 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","Purpose:\n\nThis clinical trial aims to evaluate the efficacy and safety of Lactiplantibacillus plantarum LM1001 in improving muscle strength in older adults. The study is designed to investigate its potential effects on muscle strength based on the gut-muscle axis.\n\nMethodology:\n\nThis study is a randomized, double-blind, placebo-controlled, single-center clinical trial. A total of 100 participants will be enrolled and randomly assigned to either the test group (n=50) or the placebo group (n=50). Participants in the test group will receive 500 mg of Lactiplantibacillus plantarum LM1001 (1.0 × 10¹⁰ CFU\u002Fday) once daily for 12 weeks, while those in the placebo group will receive a matching placebo.\n\nKey Outcome Measures:\n\nTo evaluate the effects on muscle strength, the following parameters will be assessed at baseline and after the 12-week intervention period:\n\n\\- Primary Outcome Measures: Changes in isokinetic knee extension and flexion strength.\n\n\\- Secondary Outcome Measures: Changes in muscle strength-related parameters, including muscle power, skeletal muscle mass (SMM), and skeletal muscle mass index (SMI), as well as physical performance measures such as handgrip strength, Short Physical Performance Battery (SPPB) score, Timed Up and Go (TUG) test, and health-related quality of life assessed by EQ-5D-5L.\n\n\\- Safety Assessments: Safety will be evaluated based on the incidence of adverse events, serum biochemical parameters, and clinical laboratory test results.",[28],"Age-Related Muscle Weakness",[30,31,32,33],"probiotics","Lactiplantibacillus plantarum","Age-related muscle weakness","Gut-muscle axis","RECRUITING","2026-04-22",{"date":37,"type":38},"2026-04-27","ACTUAL",{"date":40,"type":38},"2026-01-27",{"date":42,"type":22},"2026-12-31",{"name":44,"class":45},"Lactomason Co., Ltd.","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":46},"100631287","effect-of-l-reuteri-lm1063-on-sleep-health-improvement-100631287","NCT07498712","Effect of L. Reuteri LM1063 on Sleep Health Improvement","Effect and Safety of Limosilactobacillus Reuteri LM1063 Supplementation on the Improvement of Sleep Health: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n* Healthy male or female adults aged 19 to 65.\n* Pittsburgh Sleep Quality Index (PSQI) score of 5 or higher.\n* Voluntarily agreed to participate and signed the informed consent form.\n\nExclusion Criteria:\n\n* Severe sleep disorders (Insomnia Severity Index ≥ 22 or ≤ 7).\n* Medical conditions causing sleep disorders (Sleep apnea, Restless legs syndrome, Depression, Narcolepsy, etc.).\n* Intake of medications affecting sleep within 1 month before the first visit.\n* Intake of probiotics or fermented milk products within 1 month before the first visit.","19 Years","65 Years",{"count":57,"type":22},80,[25],"Purpose:\n\nThe purpose of this clinical trial is to evaluate the efficacy and safety of Limosilactobacillus reuteri LM1063 on improving sleep health in healthy adults. Based on the microbiota-gut-brain axis, this study aims to scientifically analyze whether the supplementation of this specific probiotic strain can enhance sleep quality.\n\nMethodology:\n\nThis is a randomized, double-blind, placebo-controlled, single-center clinical trial. A total of 80 participants (40 in the test group and 40 in the control group) will be enrolled. Participants in the test group will consume 500 mg of L. reuteri LM1063 (1.0 x 10\\^10 CFU\u002Fday) once daily for 8 weeks, while the control group will receive a placebo.\n\nKey Evaluations:\n\nTo assess sleep improvement, various parameters will be measured before and after the 8-week intake period:\n\n* Primary Outcomes: Polysomnography (PSG) measures including sleep efficiency (SE), sleep latency (SL), total sleep time (TST), wake after sleep onset (WASO), and delta power; and the Pittsburgh Sleep Quality Index (PSQI).\n* Secondary Outcomes: Various sleep and stress-related scales (SSS, ESS, PSS, RSQ-W, FSS) and blood biomarkers such as melatonin, GABA, and serotonin levels.\n* Safety: Monitored through adverse events, vital signs, and clinical laboratory tests.",[61,62],"Sleep Quality","Sleep Wake Disorders",[30,64,65,66,67],"Limosilactobacillus reuteri","sleep health","L. reuteri LM1063","gut-brain axis","2026-03-23",{"date":70,"type":38},"2026-03-27",{"date":72,"type":38},"2025-07-14",{"date":74,"type":22},"2026-06-30",{"name":44,"class":45},""]